Provided by Tiger Trade Technology Pte. Ltd.

Rigel Pharmaceuticals

34.15
+0.93002.80%
Post-market: 34.150.00000.00%19:20 EST
Volume:353.85K
Turnover:12.08M
Market Cap:619.87M
PE:5.51
High:35.00
Open:33.46
Low:33.46
Close:33.22
52wk High:52.24
52wk Low:15.50
Shares:18.15M
Float Shares:16.30M
Volume Ratio:1.20
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.20
EPS(LYR):0.9947
ROE:220.06%
ROA:38.93%
PB:5.27
PE(LYR):34.33

Loading ...

Rigel Pharmaceuticals Sets New Board Compensation Package with Stock Options and Retainers

Reuters
·
Feb 04

Rigel Pharmaceuticals beruft Michael P. Miller in den Vorstand

Reuters
·
Feb 03

Rigel Appoints Michael P. Miller to the Board of Directors

THOMSON REUTERS
·
Feb 03

H.C. Wainwright Reaffirms Their Buy Rating on Rigel (RIGL)

TIPRANKS
·
Jan 28

Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance

Simply Wall St.
·
Jan 17

Rigel Pharmaceuticals Inc : Citigroup Raises Target Price to $71 From $69

THOMSON REUTERS
·
Jan 14

Rigel Pharmaceuticals prelim Q4 revenue beats estimates

Reuters
·
Jan 12

Rigel Pharmaceuticals sees Q4 revenue $69.8M, consensus $66.44M

TIPRANKS
·
Jan 12

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M

TIPRANKS
·
Jan 12

Rigel Pharmaceuticals Projects 2026 Revenue Up to $290 Million with Positive Net Income

Reuters
·
Jan 12

Rigel Pharmaceuticals Inc - Reports Q4 Prelim Revenue of $69.8 Mln

THOMSON REUTERS
·
Jan 12

Rigel Pharmaceuticals Inc FY2026 REV View $291.6 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

Rigel Pharmaceuticals Q4 Revenue USD 69.8 Million VS. Ibes Estimate USD 64.8 Million

THOMSON REUTERS
·
Jan 12

Press Release: Rigel Provides Business Update and 2026 Outlook

Dow Jones
·
Jan 12

BRIEF-Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jan 09

Rigel Pharmaceuticals Grants Stock Options and RSUs to New Employees

Reuters
·
Jan 09

Rigel Pharmaceuticals Inc : Jefferies Raises Target Price to $50 From $42

THOMSON REUTERS
·
Dec 22, 2025

Rigel Pharmaceuticals Reports Updated Phase 1b Data for R289 in Lower-Risk MDS Patients

Reuters
·
Dec 11, 2025

Rigel Pharmaceuticals Reports Promising Phase 1b Results for R289 in Lower-Risk MDS Patients

Reuters
·
Dec 07, 2025

Rigel Presents Updated Data From the Ongoing Phase 1B Study Evaluating R289 in Patients With Lower-Risk Mds at the 67TH Ash Annual Meeting and Exposition

THOMSON REUTERS
·
Dec 07, 2025